Rational antibiotic use in COPD exacerbations

01 January 2019 → 31 December 2022
Regional and community funding: Special Research Fund
Research disciplines
  • Medical and health sciences
    • Inflammation
    • Respiratory medicine
    • Inflammation
    • Bacteriology
    • Respiratory medicine
    • Health management
    • Public health sciences not elsewhere classified
    • Health counselling
    • Inflammation
    • Respiratory medicine
COP exacerbations antibiotics benefit-risk ratio precision medicine
Project description

The disease severity and socio-economic impact of COPD is determined by acute exacerbations. More than 70% of COPD patients with acute exacerbations in primary care are treated with antibiotics, although the causal role of bacteria is often uncertain and evidence for use limited. Through population research, we want to optimize and personalize the risk-benefit ratio of antibiotic treatment in COPD.